Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GCK | P35557 | 7/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.40 |
| ▸ | EP300 | Q09472 | 1/20 | 0.37 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3592397 | 0.88 | KMT2A (0.45) | KMT2AMEN1GCKCREBBPEP300 | |
| SCHEMBL3600890 | 0.82 | GCK (0.42) | KMT2AMEN1GCKKDM4C | |
| SCHEMBL3588747 | 0.80 | GCK (0.50) | KMT2AMEN1GCK | |
| SCHEMBL2175061 | 0.79 | GCK (0.49) | KMT2AMEN1GCK | |
| SCHEMBL3601976 | 0.76 | KMT2A (0.41) | KMT2AMEN1CREBBPEP300PTGER4 | |
| SCHEMBL3592401 | 0.75 | KMT2A (0.42) | KMT2AMEN1CREBBPEP300PTGER4 | |
| SCHEMBL3605375 | 0.75 | GCK (0.49) | GCKPLA2G2A | |
| SCHEMBL3595570 | 0.74 | GCK (0.37) | KMT2AGCKPLA2G2A | |
| SCHEMBL2172360 | 0.74 | GCK (0.37) | KMT2AGCKPLA2G2A | |
| SCHEMBL3607258 | 0.72 | GCK (0.34) | KMT2AMEN1GCKKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700640-B2 | Process for making phenoxy benzamide compounds | ASTRAZENECA AB (SE) | 2010-04-20 | — | — | US | disclosed |
| US-20080200694-A1 | Process for Making Phenoxy Benzamide Compounds | ASTRAZENECA AB (SE) | 2008-08-21 | — | — | US | disclosed |
| EP-1802570-A1 | PROCESS FOR MAKING PHENOXY BENZAMIDE COMPOUNDS | AstraZeneca AB (SE) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006040527-A1 | PROCESS FOR MAKING PHENOXY BENZAMIDE COMPOUNDS | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200694-A1 | Process for Making Phenoxy Benzamide Compounds | PAH, MAOB, TYR | KMT2A 726/4885MEN1 2346/4885GCK 1415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.